If you expressed a need to control your psoriasis symptoms quickly, clear or almost clear skin is possible in 2 weeks with ULTRAVATE® Lotion.1
Additional benefits of ULTRAVATE® Lotion include:
- Moisturizes dry, thick plaques1-5
- Spreadability of a lotion suitable for large body surfaces3,4
- Appropriate treatment for elbows and knees1
Yes, ULTRAVATE® Lotion has established safety in patients 12 years of age and older. All patients should limit use to 50 g/week. Treatment beyond two weeks is not recommended.*
*Pediatric patients may be more susceptible than adults to systemic toxicity from the use of topical corticosteroids due to their larger surface-to-body mass ratios. The use of topical corticosteroids may require that patients be evaluated periodically for evidence of HPA axis suppression.1
Apply a thin layer of ULTRAVATE® Lotion to the affected skin twice daily for up to two weeks. Rub in gently.
Treatment beyond two weeks is not recommended.1
Halobetasol propionate is the active ingredient in ULTRAVATE® Lotion. It is a corticosteroid that can help reduce the signs and symptoms of plaque psoriasis.1
- Clear or almost clear skin is possible in 2 weeks.1
- Moisturizes dry, thick plaques.1-5
- ULTRAVATE® Lotion is the only class 1 corticosteroid lotion that is approved to treat plaque psoriasis in patients 12 years of age and older.4
Yes! Learn how you can pay less for your ULTRAVATE® Lotion prescriptions.
Yes, ULTRAVATE® Lotion is easily spreadable while increasing absorption into the skin.1-3,5,6
References: 1. ULTRAVATE® Lotion [prescribing information]. Cranbury, NJ: Sun Pharmaceutical Industries, Inc.; 2020. 2. National Psoriasis Foundation. Topical steroid potency chart. https://www.psoriasis.org/potency-chart/. Accessed September 25, 2020. 3. Grove G, Zerweck C, Houser T, et al. Occlusivity and moisturization potential of a new lotion formulation of halobetasol propionate, 0.05%. Poster presented at: 74th Annual Meeting of the American Academy of Dermatology; March 4-8, 2016; Washington, DC. 4. Sun Pharmaceutical Industries, Inc. Data on file. 2020. 5. Pariser D, Bukhalo M, Guenthner S, et al. Two multicenter, randomized, double-blind, parallel group comparison studies of a novel enhanced lotion formulation of halobetasol propionate lotion, 0.05% versus its vehicle lotion in adult subjects with plaque psoriasis. J Drugs Dermatol. 2017;16:(3):234-240. 6. Feldman SR. Relative efficacy and interchangeability of various clobetasol propionate vehicles in the management of steroid-responsive dermatoses. Curr Ther Res Clin Exp. 2005;66(3):154-171. 7. InformedHealth.org. Eczema: steroids and other topical medications. Cologne, Germany: Institute of Quality and Efficiency in Health Care (IQWIG). 2017. Available from http://www.ncbi.nlm.nih.giv/books/NBK424899/.
INDICATIONS AND USAGE
ULTRAVATE (halobetasol propionate) Lotion is a corticosteroid indicated for the topical treatment of plaque psoriasis in patients 12 years of age and older.
IMPORTANT SAFETY INFORMATION
Usage: Limit use to 50 g/week. Discontinue treatment when control is achieved. If no improvement is seen within 2 weeks, reassess diagnosis. Treatment beyond 2 consecutive weeks is not recommended. Avoid use on the face, scalp, groin, or axillae.
Effects on Endocrine System: Reversible hypothalamic-pituitary-adrenal (HPA) axis suppression may occur, with the potential for glucocorticosteroid insufficiency during or after treatment. Systemic effects of topical corticosteroids may also include Cushing’s syndrome, hyperglycemia, and glucosuria. Systemic absorption may require evaluation for HPA axis suppression. Use of potent corticosteroids on large areas, for prolonged durations, under occlusive dressings, or on an altered skin barrier may increase systemic exposure. Children may be more susceptible to systemic toxicity when treated with topical steroids.
Local Adverse Reactions: Local adverse reactions with topical steroids may include atrophy, striae, telangiectasias, burning, itching, irritation, dryness, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection and miliaria. These may be more likely to occur with occlusive use, prolonged use or more potent corticosteroids, including ULTRAVATE.
Concomitant Skin Infections: Use an appropriate antimicrobial agent if a skin infection is present or develops.
Allergic Contact Dermatitis: Discontinue ULTRAVATE lotion if allergic contact dermatitis is established.
In clinical trials the most common adverse reactions (≥1%) were telangiectasia, application site atrophy, and headache.
To report SUSPECTED ADVERSE REACTIONS, contact Sun Pharmaceutical Industries, Inc. at 1-800-406-7984 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.